Trial Enrollment Watch — Week of July 02, 2026

This Week in Brief

Public ClinicalTrials.gov records this week show 30 new trial registrations across therapeutic areas, alongside 51 aggregate signals of enrollment distress (delays, suspensions, or protocol amendments tied to slow accrual) tracked across the same set of areas. Rare disease and oncology continue to dominate both new activity and distress counts, a pattern consistent with the operational complexity of these indications.

Distress Signals by Therapeutic Area

Aggregate distress counts this week: rare disease (20), oncology (16), endocrine (6), respiratory (3), cardiovascular (2), immunology (2), and neurology (2). Rare disease and oncology together account for roughly 70% of all distress signals logged, underscoring the persistent enrollment challenges in indications with narrow eligibility criteria and small addressable patient pools. These figures are aggregate counts only and are not attributed to any individual sponsor or program.

Notable New Registrations

NCT07673029 — GeneQuantum Healthcare (Suzhou), Phase 3, HER2-positive Breast Cancer, 70 planned sites
NCT07674654 — Kallyope Inc., Phase 3, Acute Migraine, 120 planned sites
NCT07675135 — Harmony Biosciences, Phase 3, Narcolepsy/Cataplexy/EDS/Fatigue, 14 planned sites
NCT07678775 — ML Bio Solutions, Phase 3, Limb-Girdle Muscular Dystrophy Type 2I, 20 planned sites
NCT07673887 — Astellas Pharma Global Development, Phase 3, Gastric/GEJ Adenocarcinoma
NCT07676162 — Suzhou Suncadia Biopharmaceuticals, Phase 3, Advanced Colorectal Cancer
NCT07679360 — Suzhou Suncadia Biopharmaceuticals, Phase 3, Triple Negative Breast Cancer
NCT07677514 — Jiangsu Carephar Pharmaceutical, Phase 2, Crohn's Disease, 24 planned sites

Site Selection Takeaway

The concentration of distress signals in rare disease and oncology suggests that site feasibility work in these areas should weight prior accrual performance and disease-specific referral networks more heavily than general site capacity metrics. Trials with high planned site counts (100+) in competitive indications, such as this week's migraine and oncology registrations, are especially exposed to enrollment cannibalization if regional site density is not modeled before activation.

A Note on Data

Eichor AIOS generates free preliminary site-risk snapshots from public data for teams evaluating feasibility on newly registered trials.

---

About these numbers. Individual trial facts — NCT IDs, sponsors, phases, site counts — come directly from ClinicalTrials.gov and can be verified there. Weekly totals, therapeutic-area breakdowns, enrollment-distress flags, and the overdue-results index are produced by Eichor's own daily registry scans and analysis heuristics; they are our measurements of public data, not statistics published by ClinicalTrials.gov or FDA. The 3,000-plus overdue-trials benchmark references FDA's March 2026 compliance reminders to 2,200-plus sponsors (FDA announcement). How we're built · How findings are signed.

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →
Launch offer through July 31: first full site unlock free — one per company.